What is Prometheus Biosciences?
Founded in 1995, Prometheus Biosciences operates at the intersection of precision medicine and pharmaceutical development. The company specializes in the discovery and commercialization of diagnostics, therapeutics, and pharmaceuticals tailored for patients suffering from chronic GI and autoimmune diseases. By leveraging proprietary data platforms, the organization has established a robust framework for identifying novel therapeutic targets, effectively bridging the gap between clinical diagnostics and targeted treatment protocols. Their strategic focus remains on improving patient outcomes through highly specific, data-driven medical interventions.
How much funding has Prometheus Biosciences raised?
Prometheus Biosciences has raised a total of $260M across 1 funding round:
Debt
$260M
Debt (2010): $260M, investors not publicly disclosed
Key Investors in Prometheus Biosciences
Prometheus Biosciences
Undisclosed investor participating in the funding round.
What's next for Prometheus Biosciences?
With the successful acquisition of this capital, Prometheus Biosciences is well-positioned to accelerate its research and development initiatives. The current lifecycle stage, characterized by major enterprise-level funding, suggests a transition toward scaling clinical trials and expanding the commercial footprint of its diagnostic portfolio. Future growth will likely be driven by the integration of advanced biomarker research into their therapeutic pipeline, ensuring that the company remains at the forefront of the immunology sector. Stakeholders should anticipate increased investment in regulatory pathways and potential strategic partnerships to further validate their clinical assets in the global market.
See full Prometheus Biosciences company page
